Early Data Suggest Nivolumab Has Benefits in RCC

the Cancer Therapy Advisor take:

Nivolumab, which is already being investigated as a potential treatment for non-small cell lung cancer, melanoma, head and neck cancer, glioblastoma, and both Hodgkin and non-Hodgkin lymphoma, has shown success in early trials involving patients with renal cell carcinoma (RCC). As reported by Bristol-Myers Squibb, results from the phase 2 Checkmate -010 trial demonstrated antitumor activity when used as monotherapy in patients with RCC. A second phase1b study—Checkmate -016—indicate that nivolumab was also successful when used in combination with ipilimumab in patients with RCC. Further data will be presented at ASCO 2014.